

329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354

**Figure S1: Neutralization of Omicron subvariants by vaccinee and COVID-19 patient sera, related to Figure 1. (A-F)** Comparison of the neutralizing antibody titers in HCWs between 2-dose and 3-dose booster mRNA vaccination against the D614G (A), BA.1 (B), BA.2 (C), BA.2.12.1 (D), BA.4/5 (E), and BA.2.75 (F) variants. Lines connect samples from the same HCW, the dotted lines represent the limit of quantification ( $NT_{50} = 80$ ), and significance was determined by paired, two-tailed Student's t test with Welch's correction. **(G-I)** Heatmaps display the nAb titers for HCWs 3-4 weeks after second mRNA vaccine dose (G), 1-12 weeks after mRNA vaccine booster dose (H), and for hospitalized Omicron wave COVID-19 patients (I). HCWs are indicated as 'M' for Moderna mRNA-1273 vaccinated or 'P' for Pfizer/BioNTech BNT162b2 vaccinated, and Omicron wave patients are indicated as 'U' for unvaccinated, 'V' for 2-dose vaccinated, and 'B' for vaccinated and boosted. P-values are represented as \*\* $p < 0.01$  and \*\*\*\* $p < 0.0001$ .

**Figure S2: Syncytia formation and cell surface expression of Omicron subvariants, as well as BA.2- and BA.2.75-derived single mutants, related to Figures 3 and 4. (A-C)** Fluorescence images displaying syncytia formation are presented for HEK293T-ACE2 cells 24 hr after co-transfection with a GFP expression construct and SARS-CoV-2 variant S proteins (A), BA.2 single mutants S proteins (B), or BA.2.75 single reversion mutant S proteins (C). **(D-E)** Histograms of surface staining with anti-S1 antibody of HEK293T cells expressing S proteins from BA.2 with single mutations from BA.2.75 lineage defining mutations (D) and from BA.2.75 with single reversion mutations from BA.2.75 lineage defining mutations (E).




Figure S1

